ClinicalTrials.gg
RecruitingNCT06569329Updated Sep 10, 2026

Bacterial Reduction After Supplementary Disinfection Procedures in Infected Root Canals

An interventional study of GentleWave System Root Canal Therapy and EdgePro Laser Root Canal Therapy in Dental Pulp Necroses, sponsored by Abhishek Parolia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Abhishek Parolia · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 12 studies in Dental Pulp Necrosis with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Dental Pulp Necrosis · United States.

Planned enrollment
2nd of 10
90 · median 24
Started
2024
with 1 other
No phase
6 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Abhishek Parolia

Among the 12 studies in Dental Pulp Necrosis with a site in United States, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 with no phase, and was the 11th registered.

Dental Pulp Necrosis

157 studies on the registry are indexed under Dental Pulp Necrosis; 44 are open to participants now.

Browse Dental Pulp Necrosis studies →

Open to participants now

3 of the 12 studies in Dental Pulp Necrosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Dental Pulp Necrosis studies recruiting now, 6 (40%) set no upper age limit and 7 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Dental Pulp Necrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to understand the effect that 3 different types of root canal procedures have on bacteria.

Read the detailed description

Sample Size Calculation Sample size was calculated by STATISTICA v8.0 software (StatSoft, Tulsa, OK, USA), that demonstrated 23 teeth per group are needed to show a 5% difference in bacterial levels at 90% power. Considering possible losses, ninety adult subjects will be selected.

Case Selection and Eligibility Criteria Participants will be recruited at the Endodontic Clinic at the University of Iowa. The inclusion criteria will be patients 18 years or older, teeth with intact pulp chamber walls, no response to cold and electric pulp testing and apical periodontitis.

Teeth with vital pulp, incomplete root formation, extensive crown destruction, previous endodontic treatment or intervention (pulp debridement), acute/ chronic apical abscess, internal or external resorption, non-odontogenic facial pain, periodontal probing deeper than 4 mm, advanced untreated periodontal disease or recent periodontal surgery, teeth with mobility score > 2, fracture or visible crack, patients with diabetes or immune-compromised conditions, patients who received systemic antibiotics within the last three months, or taking corticosteroids, and pregnancy will be excluded.

Study Intervention Root canal samples will be taken under strict asepsis, as described by Rodrigues et al. (21). Operative field will be disinfected using 3% hydrogen peroxide and 3% NaOCl under rubber dam isolation. Once the access cavity is prepared, 10% sodium thiosulfate solution will be injected into the pulp chamber, and the sterility control (SC) will be taken from the access cavity walls' internal surfaces using sterile paper points. This sample will be transferred aseptically to a cryotube containing RNA later (Ambion, Austin, TX) and stored at -20°C.

The first sample (S1) will be taken as the baseline quantity of bacteria before chemomechanical preparation. One ml of 10% sodium thiosulfate solution will be injected into the canal, and a sterile paper point will be introduced up to that length for 1 minute, transferred in cryotubes containing RNA later, and stored at -20°C.

The root canal will be shaped and cleaned using rotary endodontic instruments up to size 35/.04, with periodic irrigation with 5 mL of 3% NaOCl between each instrumentation. After apical preparation, the canal will be dried with sterile paper points and then washed with 1 mL of 10% sodium thiosulfate for 1 minute to inactivate NaOCl. After that, a second sample (S2) will be collected and stored as described for S1.

Teeth specimens will be randomly assigned to three groups (n=30) according to the type of supplementary disinfection approaches used: (1) GWS, (2) LAI, and (3) UAI. These devices will be used as stated above in phase 1 of this study. After using supplementary disinfection approaches, a third sample (S3) will be collected from the root canal and stored as described above for S1 and S2.

03

Conditions studied

  • Dental Pulp Necroses

Browse trials for

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of pulp necrosis with apical periodontitis (AP) confirmed by pulp tests, clinical and radiographic evidence.
  • Tooth with no response to cold and electric pulp testing (done at screening).
  • Single canalled premolars with intact pulp chamber walls.
  • Patient must be 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Teeth with vital pulp.
  • Teeth with incomplete root formation (immature with apical periodontitis).
  • Teeth with extensive crown destruction.
  • Teeth with previous endodontic treatment or intervention (pulp debridement).
  • Teeth with acute/ chronic apical abscess.
  • Teeth with internal or external resorption.
  • Teeth with non-odontogenic facial pain.
  • Teeth with periodontal pockets deeper than 4 mm.
  • Teeth with advanced untreated periodontal disease or recent periodontal surgery.
  • Teeth with mobility score greater than 2.
  • Teeth with a fracture or visible crack.
  • Patients with diabetes or immune compromised conditions.
  • Patients who received systemic antibiotics within the last 3 months.
  • Patients taking .
  • Patients who are pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    GentleWave System Root Canal Therapy

    Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the GentleWave System root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.

    Device: GentleWave System Root Canal Therapy

  • Experimental
    EdgePro Laser Root Canal Therapy

    Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the EdgePro Laser root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.

    Device: EdgePro Laser Root Canal Therapy

  • Experimental
    The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy

    Sterile paper points will be inserted into the root canal at 3 time points: (i) before instrumentation, (ii) after washing the canal with 10% sodium thiosulfate, and (iii) after the ProUltra Piezo Ultrasonic with EndoUltra Tips root canal therapy has been completed. The paper points will collect bacteria, which will be analyzed via real-time Polymerase Chain Reaction to assess bacterial counts.

    Device: The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy

Interventions

  • DeviceGentleWave System Root Canal Therapy

    This device has 510k market approval for its intended use within this study.

  • DeviceEdgePro Laser Root Canal Therapy

    This device has 510k market approval for its intended use within this study.

  • DeviceThe ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy

    This device has 510k market approval for its intended use within this study.

06

What researchers measure

Primary outcomes

  1. Assessment of the changes in the bacterial count at various time points during the root canal procedure.

    Sterile paper points will be inserted into the root canal in order to collect bacteria. Real-time Polymerase Chain Reaction will be used to assess the bacterial counts.

    Time frame: Baseline (pre-intervention) and during the intervention and immediately after the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2028, 48 months after the start.

Of 66 non-industry interventional studies with no phase under Dental Pulp Necrosis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 48 months is above that.

Counting every sponsor, half of 67 studies reached it within 15 months; a quarter within 9 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartActual
Aug 20, 2024
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06569329
Lead sponsor
Abhishek Parolia
Responsible party
Abhishek Parolia (Associate Professor, University of Iowa) — Sponsor-investigator
First posted
Aug 26, 2024
Start date
Aug 20, 2024
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Abhishek Parolia, PhD, MDS
Contact
abhishek-parolia@uiowa.edu
(319) 335-7471
Abhishek Parolia, PhD, MDS
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion